MELBOURNE, Sept 20 (Reuters) - Australian cancer drugs maker Mayne Pharma Ltd. (MYP.AX: Quote, Profile, Research) has received an over A$2 billion ($1.5 billion) takeover approach from an international rival, the Australian Financial Review newspaper reported on Wednesday.
